SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Parks DJ, Blanchard SG, Bledsoe RK et al. Bile acids. Natural ligands for an orphan nuclear receptor. Science 284(5418), 1365–1368 (1999).
  Medline CASGoogle Scholar
• 2 Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3(5), 543–553 (1999).
  Medline CASGoogle Scholar
• 3 Makishima M. Identification of a nuclear receptor for bile acids. Science 284(5418), 1362–1365 (1999).
  Medline CASGoogle Scholar
• 4 Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl Acad. Sci. USA 101(10), 3668–3673 (2004).
  Medline CASGoogle Scholar
• 5 Chiang JY. Regulation of bile acid synthesis. Front. Biosci. 3, d176–d193 (1998).
  Medline CASGoogle Scholar
• 6 Ananthanarayanan M, Balasubramanian N, Makishima M et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276(31), 28857–28865 (2001).
  Medline CASGoogle Scholar
• 7 Landrier J, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290(3), G476–85 (2006).
  Medline CASGoogle Scholar
• 8 Zollner G, Wagner M, Moustafa T et al. Coordinated induction of bile acid detoxification and alternative elimination in mice. role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290(5), G923–32 (2006).
  Medline CASGoogle Scholar
• 9 Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart J, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17(2), 259–272 (2003).
  MedlineGoogle Scholar
• 10 Fuchs M. Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J. Lipids 2012, 934396 (2012).
  MedlineGoogle Scholar
• 11 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109(9), 1125–1131 (2002).
  Medline CASGoogle Scholar
• 12 Yamagata K, Daitoku H, Shimamoto Y et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279(22), 23158–23165 (2004).
  Medline CASGoogle Scholar
• 13 Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 582(1), 10–18 (2008). • Nice review summing up the importance of farnesoid X receptor (FXR) as a new metabolic target.
  Medline CASGoogle Scholar
• 14 Zhang Y, Lee FY, Barrera G et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103(4), 1006–1011 (2006).
  Medline CASGoogle Scholar
• 15 Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116(4), 1102–1109 (2006).
  Medline CASGoogle Scholar
• 16 Düfer M, Horth K, Wagner R et al. Bile acids acutely stimulate insulin secretion of mouse -cells via farnesoid X receptor activation and KATP channel inhibition. Diabetes 61(6), 1479–1489 (2012).
  Medline CASGoogle Scholar
• 17 Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabol. 10(3), 167–177 (2009).
  Medline CASGoogle Scholar
• 18 Kumar DP, Rajagopal S, Mahavadi S et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem. Biophys. Res. Commun. 427(3), 600–605 (2012).
  Medline CASGoogle Scholar
• 19 Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165(2), 414–423 (2012).
  Medline CASGoogle Scholar
• 20 Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484–489 (2006).
  Medline CASGoogle Scholar
• 21 Merk D, Steinhilber D, Schubert-Zsilavecz M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem. 4(8), 1015–1036 (2012). • A key overview of the medicinal chemistry of FXR ligands.
  CASGoogle Scholar
• 22 Lamers C, Schubert-Zsilavecz M, Merk D. Medicinal chemistry and pharmacological effects of farnesoid X receptor (FXR) antagonists. Curr. Top. Med. Chem. 14(19), 2188–2205 (2014). • Review of potential pharmacological use of FXR antagonism and the medicinal chemistry of FXR antagonists.
  Medline CASGoogle Scholar
• 23 Carotti A, Marinozzi M, Custodi C et al. Beyond bile acids. Targeting farnesoid X receptor (FXR) with natural and synthetic ligands. Curr. Top. Med. Chem. 14(19), 2129–2142 (2014).
  Medline CASGoogle Scholar
• 24 Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 17(17–18), 988–997 (2012).
  Medline CASGoogle Scholar
• 25 Mudaliar S, Henry RR, Sanyal AJ et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with Type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145(3), 574–82.e1 (2013).
  Medline CASGoogle Scholar
• 26 Hirschfield GM, Mason A, Luketic V et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148(4), 751.e8–761.e8 (2015). •• First promising Phase III clinical data of a FXR agonist in the treatment of primary biliary cirrhosis.
  Google Scholar
• 27 Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT). A multicentre, randomised, placebo-controlled trial. Lancet 385(9972), 956–965 (2015).
  Medline CASGoogle Scholar
• 28 Singh N, Yadav M, Singh AK et al. Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors. Mol. Endocrinol. 28(5), 659–673 (2014).
  MedlineGoogle Scholar
• 29 Akwabi-Ameyaw A, Bass JY, Caldwell RD et al. Conformationally constrained farnesoid X receptor (FXR) agonists. Naphthoic acid-based analogs of GW 4064. Bioorg. Med. Chem. Lett. 18(15), 4339–4343 (2008).
  Medline CASGoogle Scholar
• 30 Chiang P, Thompson DC, Ghosh S, Heitmeier MR. A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys. J. Pharm. Sci. 100(11), 4722–4733 (2011).
  Medline CASGoogle Scholar
• 31 Howarth DL, Law SH, Law JM, Mondon JA, Kullman SW, Hinton DE. Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes). Toxicol. Appl. Pharmacol. 243(1), 111–121 (2010).
  Medline CASGoogle Scholar
• 32 Urizar NL. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296(5573), 1703–1706 (2002).
  Medline CASGoogle Scholar
• 33 Cui J. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278(12), 10214–10220 (2003).
  Medline CASGoogle Scholar
• 34 Lamers C, Schubert-Zsilavecz M, Merk D. Medicinal chemistry and pharmacological effects of farnesoid X receptor (FXR) antagonists. Curr. Top. Med. Chem. 14(19), 2188–2205 (2014).
  Medline CASGoogle Scholar
• 35 Watanabe M, Horai Y, Houten SM et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286(30), 26913–26920 (2011).
  Medline CASGoogle Scholar
• 36 Pellicciari R, Gioiello A, Macchiarulo A et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52(24), 7958–7961 (2009).
  Medline CASGoogle Scholar
• 37 Sato H, Genet C, Strehle A et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 362(4), 793–798 (2007).
  Medline CASGoogle Scholar
• 38 Gioiello A, Rosatelli E, Nuti R, Macchiarulo A, Pellicciari R. Patented TGR5 modulators: a review (2006–present). Expert Opin. Ther. Patents 22(12), 1399–1414 (2012). • Review of TGR5 ligands in patent literature.
  Medline CASGoogle Scholar
• 39 Rizzo G, Passeri D, de Franco F et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78(4), 617–630 (2010).
  Medline CASGoogle Scholar
• 40 Piotrowski DW, Futatsugi K, Warmus JS et al. Identification of tetrahydropyrido[4,3- d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists. ACS Med. Chem. Lett. 4(1), 63–68 (2013).
  Medline CASGoogle Scholar
• 41 Lieu T, Jayaweera G, Zhao P et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147(6), 1417–1428 (2014).
  Medline CASGoogle Scholar
• 42 Cipriani S, Renga B, D'Amore C et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS ONE 10(7), e0129866 (2015).
  MedlineGoogle Scholar
• 43 Fang S, Suh JM, Reilly SM et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21(2), 159–165 (2015).
  Medline CASGoogle Scholar
• 44 Merk D, Zettl M, Steinhilber D, Werz O, Schubert-Zsilavecz M. Pirinixic acids – flexible fatty acid mimetics with various biological activities. Future Med. Chem. 7(12), 1597–1616 (2015).
  CASGoogle Scholar
• 45 Zettl H, Steri R, Lämmerhofer M, Schubert-Zsilavecz M. Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists. Bioorg. Med. Chem. Lett. 19(15), 4421–4426 (2009).
  Medline CASGoogle Scholar
• 46 Steri R, Achenbach J, Steinhilber D, Schubert-Zsilavecz M, Proschak E. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem. Pharmacol. 83(12), 1674–1681 (2012).
  Medline CASGoogle Scholar
• 47 Seuter S, Väisänen S, Rådmark O, Carlberg C, Steinhilber D. Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. Biochim. Biophys. Acta 1771(7), 864–872 (2007).
  Medline CASGoogle Scholar
• 48 Rau O, Wurglics M, Paulke A et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Med. 72(10), 881–887 (2006).
  Medline CASGoogle Scholar
• 49 Merk D, Lamers C, Ahmad K et al. Extending the structure–activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators. development of a highly potent partial farnesoid X receptor agonist. J. Med. Chem. 57(19), 8035–8055 (2014).
  Medline CASGoogle Scholar
• 50 Schmidt J, Klingler F, Proschak E, Steinhilber D, Schubert-Zsilavecz M, Merk D. NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with farnesoid X receptor. Sci. Rep. 5, 14782 (2015).
  Medline CASGoogle Scholar
• 51 Qi Y, Jiang C, Cheng J et al. Bile acid signaling in lipid metabolism. Metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochim. Biophys. Acta 1851(1), 19–29 (2014).
  MedlineGoogle Scholar
• 52 Fiorucci S, Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25(3), 252–259 (2009).
  Medline CASGoogle Scholar
• 53 de Gottardi A, Touri F, Maurer CA et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci. 49(6), 982–989 (2004).
  Medline CASGoogle Scholar
• 54 Silva J, Dasgupta S, Wang G, Krishnamurthy K, Ritter E, Bieberich E. Lipids isolated from bone induce the migration of human breast cancer cells. J. Lipid Res. 47(4), 724–733 (2006).
  Medline CASGoogle Scholar
• 55 de Gottardi A, Dumonceau J, Bruttin F et al. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol. Cancer 5, 48 (2006).
  MedlineGoogle Scholar
• 56 Capello A, Moons LMG, Winkel AV, Siersema PD, Dekken H, Kuipers EJ. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in barrett esophagus. Am. J. Gastroenterol. 103(6), 1510–1516 (2008).
  Medline CASGoogle Scholar
• 57 Journe F, Durbecq V, Chaboteaux C et al. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res. Treat. 115(3), 523–535 (2009).
  Medline CASGoogle Scholar
• 58 Lee JY, Lee KT, Lee JK et al. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br. J. Cancer 104(6), 1027–1037 (2011).
  Medline CASGoogle Scholar
• 59 Lambert G, Amar MJA, Guo G, Brewer HB, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278(4), 2563–2570 (2003).
  Medline CASGoogle Scholar
• 60 Prawitt J, Abdelkarim M, Stroeve JHM et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60(7), 1861–1871 (2011).
  Medline CASGoogle Scholar
• 61 Bjursell M, Wedin M, Admyre T et al. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS ONE 8(5), e64721 (2013).
  Medline CASGoogle Scholar
• 62 Sato H, Macchiarulo A, Thomas C et al. Novel potent and selective bile acid derivatives as TGR5 agonists. Biological screening, structure−activity relationships, and molecular modeling studies. J. Med. Chem. 51(6), 1831–1841 (2008).
  Medline CASGoogle Scholar